Innovative Nanobody Therapy Targeting Factor VIII and Factor X for Advanced Hemophilia Care
VHH-P725 is a fully humanized nanobody candidate currently in the Biological Testing stage, designed to target both coagulation factor VIII (F8) and coagulation factor X (F10). Engineered and expressed in E. coli, this single-domain antibody holds significant promise for the treatment of hemophilia. By engaging two central regulators in the coagulation cascade, VHH-P725 offers a novel therapeutic approach for patients with hemophilia, aiming to enhance coagulation pathway control and address key challenges in disease management.
| Candidate | VHH-P725 |
| Target | coagulation factor VIII (F8) coagulation factor X (F10) |
| Modality | humanized bispecific VHH |
| Indication | Hemophilia |
Licensing Opportunity
VHH-P725 is available for out-licensing and collaborative development. We invite industry partners to explore strategic alliances or licensing arrangements to accelerate the advancement and commercialization of this innovative hemophilia therapy.
Contact UsDevelopment Phase
| Program | Research | Preclinical | Phase 1 |
|---|---|---|---|
| VHH-P725 |
Modality
VHH-P725 utilizes a single domain antibody format, known as a nanobody, specifically engineered to target coagulation factor X. Produced in E. coli cells, this modular structure endows it with advantageous properties, including low molecular weight, high tissue penetrance, and exceptional stability under diverse conditions. The nanobody framework allows for superior access to cryptic or enzyme-active sites of its targets, making it especially well-suited for clotting disorder therapies. Due to its robust structure and manufacturability, VHH-P725 has the potential to offer consistent efficacy and safety in hemophilia care, overcoming certain limitations of conventional antibody modalities.
Target
Factor VIII and Factor X are critical glycoproteins central to the blood coagulation cascade. Factor VIII serves as a cofactor in the intrinsic pathway, while Factor X functions as a key enzyme in prothrombin activation during the common pathway. Both Factor VIII and Factor X are primarily synthesized in the liver and are predominantly found within the plasma. Mutations or deficiencies in Factor VIII or Factor X are directly linked to hemophilia phenotypes, making them established and valuable therapeutic targets. By concurrently targeting Factor VIII and Factor X, VHH-P725 addresses essential regulatory nodes in coagulation, providing high potential impact for hemophilia treatment strategies and reinforcing its strategic positioning in the development of novel, multi-targeted therapeutics.
Mechanism of Action
VHH-P725 exerts its therapeutic action by binding with high specificity to both Factor VIII and Factor X, pivotal elements in the blood coagulation pathway. By engaging these two targets, VHH-P725 can function as a coagulation pathway activator and may serve as a mimetic of Factor VIII activity while modulating Factor X function. This bi-modal targeting is designed to restore or compensate for deficiencies in the coagulation cascade, a hallmark of hemophilia. The single domain antibody format not only facilitates high tissue and vascular access but also enables further engineering, such as multimerization, bispecificity, or payload conjugation for expanded clinical application. This versatility aligns VHH-P725 with the next generation of highly adaptable hemophilia therapeutics.
Hemophilia
Hemophilia is a hereditary bleeding disorder characterized by deficiencies in key clotting factors, predominantly Factor VIII (hemophilia A) or Factor IX (hemophilia B), and less frequently, Factor X. Globally, hemophilia affects tens of thousands of individuals, leading to recurrent spontaneous bleeding, joint damage, and serious morbidity. Current treatment strategies primarily rely on replacement therapies, such as intravenous infusions of clotting factor concentrates, or on non-factor therapies targeting alternative hemostasis regulators. However, limitations include frequent administration, inhibitor development, risk of viral transmission, and variable pharmacokinetics. There remains a critical need for novel agents with improved safety, longer activity, and alternative mechanisms of action. VHH-P725, by simultaneously targeting Factor VIII and Factor X, is strategically positioned to address these unmet needs and advance hemophilia care beyond existing paradigms.